Long-Term Chamomile Therapy of Generalized Anxiety Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial.

  title={Long-Term Chamomile Therapy of Generalized Anxiety Disorder: A Study Protocol for a Randomized, Double-Blind, Placebo- Controlled Trial.},
  author={Jun J. Mao and Qing S Li and Irene Soeller and Kenneth Rockwell and Sharon X. Xie and Jay D. Amsterdam},
  journal={Journal of clinical trials},
  volume={4 5}
BACKGROUND Anxiety symptoms are among the most common reasons for consumers to use Complementary and Alternative Medicine (CAM) therapy. Although many botanicals have been proposed as putative remedies for anxiety symptoms, there has been a paucity of controlled trials of these remedies. A preliminary study of the anxiolytic effect of Chamomile (Matricaria recutita) in humans suggests that chamomile may have anxiolytic and antidepressant activity. We now seek to conduct a 5-year randomized… 

Tables from this paper

Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.

Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.

Putative Antidepressant Effect of Chamomile (Matricaria chamomilla L.) Oral Extract in Subjects with Comorbid Generalized Anxiety Disorder and Depression.

M. chamomilla L. (chamomile) extract may produce clinically meaningful antidepressant effects in addition to its anxiolytic activity in subjects with GAD and comorbid depression.

Phytotherapy as treatment for anxiety: An alternative to minimize addiction and side effects

Herbal medicine appears as an important alternative therapy to treat anxiety disorders because it exhibits comparable and even superior anxiolytic effects when compared to classes of drugs such as benzodiazepines, with minimization or elimination of side/adverse effects.

Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial

This Phase II randomized, double-blind, placebo-controlled trial will provide the initial evidence on the efficacy and safety of the pain-relieving plaster for pain relief among cancer survivors with chronic musculoskeletal pain.

Action mechanism of Roman chamomile in the treatment of anxiety disorder based on network pharmacology.

The target and mechanism of Roman chamomile in the treatment of anxiety were discussed, and its efficacy was verified by model animals, which not only clarified its mechanism at the systematic level, but also proved to be effective at the biological level.

Generalized anxiety: a systematic review Passiflora incarnata (passion fruit), Matricaria recutita (Chamomile) and Melissa officinalis (lemongrass)

A systematic review on Randomized, controlled clinical trials with Matricaria recutita (camomile), Melissa officinalis (Lemon balm) and Passiflora incarnata (passion fruit) for Generalized Anxiety Disorder (GAD) to identify clinical studies on the efficacy and safety.

The pharmacology and clinical efficacy of matricaria recutita L.: a systematic review of in vitro, in vivo studies and clinical trials

This systematic review shows the effectiveness of Matricaria chamomilla for improving health by validated some of these in vitro and in vivo pharmacological activities (diabetes mellitus, hypertension and pain).



A Randomized, Double-Blind, Placebo-Controlled Trial of Oral Matricaria recutita (Chamomile) Extract Therapy for Generalized Anxiety Disorder

The results suggest that chamomile may have modest anxiolytic activity in patients with mild to moderate GAD, and a positive change in all secondary outcomes in the same direction as the primary outcome measure.

Chamomile (Matricaria recutita) may provide antidepressant activity in anxious, depressed humans: an exploratory study.

Chamomile may provide clinically meaningful antidepressant activity that occurs in addition to its previously observed anxiolytic activity, as explored in this study.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

This first placebo-controlled demonstration of the long-term efficacy of any drug class in treating outpatients with DSM-IV-diagnosed GAD shows venlafaxine XR is an effective, rapidly acting, safe, once-daily agent for both the short- and long- term treatment of anxiety and may provide an important alternative to currently available anxiolytics.

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment.

Sertraline was effective in preventing relapse of generalized social phobia and future research should assess whether improvements may be maintained or further increased by longer periods of treatment or through the addition of cognitive-behavioral techniques.

Pharmacotherapy of generalized anxiety disorder.

  • J. Davidson
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2001
Treatment with antidepressants has opened up a new area of investigation into the pharmacotherapy of GAD, with a growing body of evidence supporting the role of therapies such as paroxetine and venlafaxine extended release.

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

The effects of an abrupt interruption of agomelatine, a new melatonergic/serotonergic antidepressant, were explored in a double-blind, placebo-controlled study and no significant difference was shown between the continuing and interrupting groups in the second week of discontinuation.

Safety and Efficacy of Herbal Sedatives in Cancer Care

Although sufficient evidence exists to recommend some of these agents for short-term relief of mild insomnia, long-term trials and observational studies are needed to establish the safety of prolonged use as well as overall efficacy in the context of cancer treatment and management.

Discontinuation symptoms in depression and anxiety disorders.

For each antidepressant, no differences in discontinuation symptoms were observed between the three indications and there was no evidence for increased symptom incidence with increased length of treatment, suggesting discontinuation profiles differ between antidepressants of the same class and are broadly similar in different disorders.

The long-term clinical course of generalized anxiety disorder.

  • M. Keller
  • Psychology
    The Journal of clinical psychiatry
  • 2002
It is hoped that, as with depression, long-term prospective studies in GAD will provide insight into the course, nature, and outcomes of the disorder over time, leading to increased understanding of GAD and the development of effective treatment strategies tailored for individual patients.